Avastin helps cervical cancer patients

Share this article:

Avastin and chemotherapy added four months of survival among advanced cervical cancer patients. Medpage Today reported Friday that the study, published in the New England Journal of Medicine, showed median overall survival was 17 months with Avastin vs. 13.3 using only chemotherapy. Adding Avastin to platinum-based or nonplatinum therapy did not have a significant impact on results.

“Cervical cancer patients are often mothers with minor children. This is a major advance and clinical benefit to those patients," Memorial Sloan-Kettering Cancer Center's Carol Aghajaman told Medpage.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.